Catheter Precision Announces Launch of LockeT in Switzerland
Rhea-AI Summary
Catheter Precision (NYSE/American: VTAK) announced the commercial launch of its LockeT suture retention device in Switzerland on December 1, 2025. The first clinical cases were performed at Spitalzentrum Biel under PD Dr. Rainer Zbinden with reported excellent procedural outcomes and positive staff feedback.
The launch follows a strategic distribution agreement with FuMedica AG, enabling rollout to hospitals and clinics across Switzerland and expanding Catheter Precision’s European footprint. The company noted over 10,000 LockeT units shipped globally and highlighted benefits including reduced groin management costs and support for same-day discharge.
Positive
- Signed distribution agreement with FuMedica AG to cover Switzerland
- First clinical cases at Spitalzentrum Biel reported excellent procedural outcomes
- 10,000+ LockeT units shipped globally, indicating existing commercial traction
- Potential same-day discharge and reduced groin management costs noted
Negative
- None.
News Market Reaction – VTAK
On the day this news was published, VTAK declined 3.31%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While VTAK rose 7.53%, key peers NUWE, BBLG, BJDX, VERO, and NAOV all showed negative moves today, indicating stock-specific strength rather than a broad medical devices rally.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | VIVO tender win | Positive | +13.3% | Multi-year VIVO tender at major Hungarian hospital expands European presence. |
| Dec 01 | LockeT Swiss launch | Positive | -3.3% | Commercial launch of LockeT in Switzerland with positive early clinical feedback. |
| Nov 25 | ASC reimbursement win | Positive | +12.1% | New Medicare ASC coverage for EP ablation framed as LockeT opportunity. |
| Nov 20 | LockeT South Africa | Positive | -9.9% | Rapid LockeT uptake across five South African hospitals with reorders placed. |
| Nov 13 | Q3 2025 results | Positive | -10.9% | Revenue growth and reduced quarterly loss alongside international commercialization updates. |
Positive commercial and policy wins have produced mixed reactions: some spikes on tenders and reimbursement news, but several LockeT launch updates and earnings were sold off despite constructive headlines.
Over the last month, Catheter Precision has focused on commercial expansion and reimbursement tailwinds. A Hungarian tender for the VIVO system and a U.S. reimbursement change for electrophysiology ablations both supported its European and ASC strategies, with price moves of 13.33% and 12.13%. Multiple LockeT launches, including South Africa and Switzerland, highlighted growing adoption but drew negative reactions of -9.88% and -3.31%. Q3 2025 results, showing revenue growth but ongoing losses, also saw a -10.93% move.
Market Pulse Summary
This announcement highlights another step in Catheter Precision’s European expansion, adding Switzerland to the growing list of LockeT markets and noting over 10,000 units shipped globally. Recent history shows parallel efforts in South Africa, Hungary, and policy-driven ASC opportunities in the U.S. Investors may monitor how these launches translate into revenue trends, reorder patterns, and broader adoption across new hospitals and regions.
Key Terms
cardiac electrophysiology medical
suture retention device medical
AI-generated analysis. Not financial advice.
Fort Mill, SC, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced the successful launch of its LockeT suture retention device in Switzerland.
The first clinical cases were performed at Spitalzentrum Biel, led by PD Dr. Rainer Zbinden, with excellent procedural outcomes and positive feedback from both the clinical and nursing teams. This milestone follows the company’s recent strategic distribution agreement with FuMedica AG, a premier Swiss medical device distributor with a strong presence in cardiovascular and interventional medicine. The partnership enables the introduction of LockeT to hospitals and clinics across Switzerland, further expanding Catheter Precision’s European footprint.
Fatih Ayoglu, Sales Manager EMEA & APAC at Catheter Precision, said, “We’ve recently partnered with FuMedica to distribute LockeT in Switzerland, and it’s already exciting to see the first cases roll out so quickly. LockeT is intuitive and easy to use—it reduces groin management costs and supports same-day discharge. With over 10,000 LockeTs shipped globally, we’re growing fast and working hard with our partners, one patient at a time.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
# # #
CONTACTS: Investor Relations 973-691-2000 IR@catheterprecision.com
FAQ
What did Catheter Precision (VTAK) announce on December 1, 2025 about LockeT in Switzerland?
How will the FuMedica AG distribution agreement affect Catheter Precision (VTAK) in Europe?
What clinical results were reported for LockeT's first Swiss cases reported December 1, 2025?
How many LockeT units has Catheter Precision (VTAK) shipped globally as of this announcement?
What operational benefits does LockeT claim to provide for patients and hospitals?
